Literature DB >> 24080081

Extended-spectrum beta-lactamase-producing Enterobacteriaceae carriage upon hospital admission: prevalence and risk factors.

P Shitrit1, S Reisfeld, Y Paitan, B-S Gottesman, M Katzir, M Paul, M Chowers.   

Abstract

The aim of this study was to assess the value of surveillance cultures in identifying extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL) carriers upon admission to hospital, and to identify risk factors for carriage. This prospective cross-sectional study included all hospital admissions over one week. Of 525 patients screened, 56 were positive for ESBLs. Half were only identified through screening. Four independent risk factors were identified: nursing home residency, hospitalization in the previous year, prior antibiotic treatment and prior ESBL carriage. Over 50% of the screened patients had at least one risk factor. By screening this targeted population, 87.5% of positive patients would have been identified.
Copyright © 2013 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ESBL; Risk factors; Surveillance

Mesh:

Substances:

Year:  2013        PMID: 24080081     DOI: 10.1016/j.jhin.2013.07.014

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  7 in total

1.  Community-Onset Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Invasive Infections in Children in a University Hospital in France.

Authors:  Julie Toubiana; Sandra Timsit; Agnès Ferroni; Marie Grasseau; Xavier Nassif; Olivier Lortholary; Jean-Ralph Zahar; Martin Chalumeau
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

2.  Successful control of the first carbapenem-resistant Klebsiella pneumoniae outbreak in a Chinese hospital 2017-2019.

Authors:  Jiaying Zhu; Qi Li; Xiaoxia Li; Jianbang Kang; Yan Song; Junli Song; Donghong Yin; Jinju Duan
Journal:  Antimicrob Resist Infect Control       Date:  2020-06-22       Impact factor: 4.887

3.  Admission prevalence of colonization with third-generation cephalosporin-resistant Enterobacteriaceae and subsequent infection rates in a German university hospital.

Authors:  Anne-Cathérine Boldt; Frank Schwab; Anna M Rohde; Axel Kola; Minh Trang Bui; Nayana Märtin; Marina Kipnis; Christin Schröder; Rasmus Leistner; Miriam Wiese-Posselt; Janine Zweigner; Petra Gastmeier; Luisa A Denkel
Journal:  PLoS One       Date:  2018-08-01       Impact factor: 3.240

4.  Local prevalence of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae intestinal carriers at admission and co-expression of ESBL and OXA-48 carbapenemase in Klebsiella pneumoniae: a prevalence survey in a Spanish University Hospital.

Authors:  Cristina Díaz-Agero Pérez; Nieves López-Fresneña; Angela L Rincon Carlavilla; Marta Hernandez Garcia; Patricia Ruiz-Garbajosa; Jesús María Aranaz-Andrés; Friederike Maechler; Petra Gastmeier; Marc J M Bonten; Rafael Canton
Journal:  BMJ Open       Date:  2019-03-01       Impact factor: 2.692

5.  Modelling and Simulation of the Effect of Targeted Decolonisation on Incidence of Extended-Spectrum Beta-Lactamase-Producing Enterobacterales Bloodstream Infections in Haematological Patients.

Authors:  Stefanie Döbele; Fulvia Mazzaferri; Tamara Dichter; Gerolf de Boer; Alex Friedrich; Evelina Tacconelli
Journal:  Infect Dis Ther       Date:  2021-10-19

6.  Trends in Extended Spectrum Beta-Lactamase (ESBL) Producing Enterobacteriaceae and ESBL Genes in a Dutch Teaching Hospital, Measured in 5 Yearly Point Prevalence Surveys (2010-2014).

Authors:  Ina Willemsen; Stijn Oome; Carlo Verhulst; Annika Pettersson; Kees Verduin; Jan Kluytmans
Journal:  PLoS One       Date:  2015-11-03       Impact factor: 3.240

7.  Extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) isolated from bean sprouts in the Netherlands.

Authors:  Pepijn Huizinga; Eefje Schrauwen; Silvia García-Cobos; Ina Willemsen; Carlo Verhulst; Alexander W Friedrich; Paul H M Savelkoul; John W Rossen; Jan Kluytmans
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.